Systematic Review
Published on 03 Mar 2023
Prognostic value of nectin-4 in human cancers: A meta-analysis
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1081655
- 5,214 views
- 7 citations
Type at least 3 characters
1,441 articles
Original Research
Published on 03 Mar 2023
Identification of the novel therapeutic targets and biomarkers associated of prostate cancer with cancer-associated fibroblasts (CAFs)
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1136835
- 5,137 views
- 13 citations
Original Research
Published on 28 Feb 2023
Metabolic classification of non-small cell lung cancer patient-derived xenografts by a digital pathology approach: A pilot study
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1070505
- 2,548 views
- 2 citations
Original Research
Published on 27 Feb 2023
Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1124039
- 8,137 views
- 13 citations
Original Research
Published on 27 Feb 2023
Clinical management of molecular alterations identified by high throughput sequencing in patients with advanced solid tumors in treatment failure: Real-world data from a French hospital
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1104659
- 2,626 views
- 6 citations
Original Research
Published on 23 Feb 2023
Potential use of TG68 - A novel thyromimetic - for the treatment of non-alcoholic fatty liver (NAFLD)-associated hepatocarcinogenesis
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1127517
- 5,325 views
- 9 citations
Original Research
Published on 23 Feb 2023
Association of circulating tumor cells and IMP3 expression with metastasis of osteosarcoma
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.819357
- 2,670 views
- 11 citations
Original Research
Published on 23 Feb 2023
Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway)
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.860711
- 4,558 views
- 5 citations
Case Report
Published on 22 Feb 2023
Case Report: The effective treatment of patients in advanced no-small cell lung cancer patients with EGFR G719X/S768I/L861Q and acquired MET amplification: A case series and literature review
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1126325
- 3,129 views
- 3 citations
Original Research
Published on 22 Feb 2023
The efficacies and biomarker investigations of antiangiogenic agents and PD-1 inhibitors for metastatic soft tissue sarcoma: A multicenter retrospective study
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1124517
- 2,212 views
- 7 citations
Mini Review
Published on 20 Feb 2023
ARID1A in cancer: Friend or foe?
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1136248
- 15,674 views
- 28 citations
Review
Published on 16 Feb 2023
Serum cytokine levels and other associated factors as possible immunotherapeutic targets and prognostic indicators for lung cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1064616
- 4,501 views
- 6 citations
Original Research
Published on 16 Feb 2023
Molecular features and predictive models identify the most lethal subtype and a therapeutic target for osteosarcoma
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1111570
- 3,844 views
- 4 citations
Case Report
Published on 13 Feb 2023
Positive response to niraparib in chemo-refractory patients with metastatic appendiceal mucinous adenocarcinoma harboring ATM mutations: A case report
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1010871
- 1,884 views
- 2 citations
Original Research
Published on 10 Feb 2023
High GNG4 predicts adverse prognosis for osteosarcoma: Bioinformatics prediction and experimental verification
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.991483
- 3,964 views
- 2 citations
Clinical Trial
Published on 09 Feb 2023
Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1107307
- 3,413 views
- 2 citations